Allgens Medical Technology Co., Ltd.

Allgens Medical Technology Co., Ltd. was established in 2004. It is a Sino-foreign joint venture of medical devices focusing on R&D, production and sales of tissue engineering materials, mainly involving new biodegradable materials. The company has been recognized as a high-tech enterprise in Beijing, a national high-tech enterprise, and was selected as an innovation leading enterprise in the Beijing Biomedical Industry Leap-over Development Project (G20 Project). The company has a 10,000-level clean production workshop, and has established a strict quality management system in accordance with the "Medical Device Manufacturing Quality Management Standard (GMP) Implantable Medical Device Implementation Rules" and YY/T 0287 requirements, and has passed the GMP audit certification of CFDA and international quality management system certification, ISO13485 and ISO9001. Allgens is a national high-tech enterprise dedicated to the R&D, production and sales of high-end implantable medical devices for tissue regeneration and repair. Relying on the patented technology of Tsinghua University and more than ten years of independent research and development accumulation, a series of biomimetic mineralized collagen artificial bone repair products have been developed, covering four major categories of orthopedics, stomatology, plastic surgery, and neurosurgery, with more than 50 varieties . The company's products and technologies now have more than 50 Chinese patents and more than 10 overseas patents. In May 2021, it successfully listed on SSE STAR Market (Stock code:688613). With its excellent R&D capabilities and expanding productivity, ALLGENS has created a miracle of the rapid development of domestic medical device companies in China.

• Employees 280
• Founded 2004
• Annual Revenue $28226000